openFDA
Cure8 regulatory brief
Tofacitinib FDA label update (2026-08-06)
Medications
Tofacitinib
Steroids
JAK inhibitor
Regulatory Update
Adult patients
Clinicians
Ulcerative colitis
Why This Matters
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety warnings that affect treatment decisions and monitoring.
Who Should Pay Attention
Adults with ulcerative colitis considering or taking tofacitinib; clinicians prescribing JAK inhibitors for IBD; caregivers of patients on immunosuppressive therapy.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA (DailyMed) drug label update for tofacitinib (a JAK inhibitor) with boxed warnings and indications including ulcerative colitis. The extract is from the official prescribing information and describes indications, limitations of use, and safety warnings (serious infections, mortality, malignancy, cardiovascular events, and thrombosis).
Keep In Mind
This record is the FDA-approved prescribing information (regulatory-record). It summarizes approved indications and boxed safety warnings; it is not a clinical trial report. Recommendations and safety statements reflect the label and should be discussed with a prescribing clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorMacleods Pharmaceuticals Limited
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 6, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tofacitinib FDA label update (2026-07-27)
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
TOFACITINIB FDA label update (2026-07-31)
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
The JAK attack: transforming the management of ulcerative colitis in India
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...